Efficacy of sacubitril/valsartan versus valsartan in patients with arterial hypertension
https://doi.org/10.18705/1607-419X-2024-2375
EDN: VHPBYX
Abstract
Objective. To identify the effectiveness of sacubitril/valsartan versus valsartan in reducing blood pressure (BP) in patients with arterial hypertension (HTN) 1–2 degree.
Design and methods. The study included 105 patients, among them 90 were included in the effectiveness analysis and were observed for 12 months in an outpatient setting. In accordance with the protocol, 90 patients completed the study, 44 of them received sacubitril/ valsartan (97/103 mg), 46 received valsartan (160 mg). The dynamics of clinical BP in mm Hg and rates of achieving target BP levels in treatment groups were assessed.
Results. Systolic after 12 months decreased more significantly in sacubitril/valsartan group versus valsartan: by 14,68 ± 9,33 vs 6,17 ± 4,81 mmHg (p = 0,007). The rate of achieving target BP was higher in the sacubitril/valsartan group (61,41 % vs 34,8 %, p < 0,01).
Conclusions. Among patients with 1–2 degree HTN, sacubitril/valsartan reduced blood pressure to a greater extent than valsartan alone and was not inferior to the latter in terms of safety criteria.
About the Authors
A. S. Ryazanov
Russian Medical Academy of Continuing Professional Education
Russian Federation
Russian Federation
Alexey S. Ryazanov, MD, PhD, DSc, Professor, Head, Department of General Medical Practice and Outpatient Therapy
Moscow
L. V. Melnikova
Russian Medical Academy of Continuing Professional Education
Russian Federation
Russian Federation
Lyudmila V. Melnikova, MD, PhD, DSc, Professor, Professor of the Department of General Medical Practice and Outpatient Therapy
Moscow
M. V. Makarovskaya
Russian Medical Academy of Continuing Professional Education;
GBUZ Clinical Diagnostic Center No. 4 DZM
Russian Federation
Russian Federation
Maria V. Makarovskaya, MD, Assistant, Department of General Medical Practice and Outpatient Therapy, Russian Medical Academy of Postgraduate Education
3, Krylatskie holmy str., Moscow, 121609
O. V. Kechina
GBUZ Clinical Diagnostic Center No. 4 DZM
Russian Federation
Russian Federation
Olga V. Kechina, MD, Chief Physician
Moscow
References
1. Writing Group Members, Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, et al. Heart disease and stroke statistics –– 2016 update: a report from the American Heart Association. Circulation. 2016; 133:e38 e360. doi:10.1161/CIR.0000000000000350
2. Balanova YuA, Drakina OM, Kutsenko VA, Imaeva AE, Kontsevaya AV, Maksimov SA et al. Arterial hypertension in the Russian population during the COVID 19 pandemic: gender differences in prevalence, treatment and its effectiveness. Research data from ESSE-RF3. Cardiovascular Therapy and Prevention. 2023;22(8S):3785. doi:10.15829/1728-8800-2023-3785. In Russian.
3. Kobalava ZD, Konradi AO, Nedogoda SV, Shlyakhto EV, Arutyunov GP, Baranova EI at al. Arterial hypertension in adults. Clinical guidelines 2020. Russian Journal of Cardiology. 2020;25(3):3786. doi:10.15829/1560-4071-2020-3-3786. In Russian.
4. Maltseva AS, TsygankovaAE, Gabitova MA, Rodionov AV, FominVV. Treatment of Resistant Hypertension in Real Clinical Settings. Ratsionalnaya Farmakoterapiya v Kardiologii = Rational Pharmacotherapy in Cardiology. 2021;17(2):200–205. In Russian.
5. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. J Hypertens. 2018;36(10):1953–2041.
6. Global report on hypertension: the race against a silent killer. Geneva: World Health Organization; 2023. Licence: CC BY-NC-SA 3.0 IGO. ISBN:978-92-4-008106-2
7. Geldsetzer P, Manne-Goehler J, Marcus ME, Ebert C, Zhumadilov Z, Wesseh CS et al. The state of hypertension care in 44 low-income and middle-income countries: a cross-sectional study of nationally representative individual-level data from 1·1 million adults. Lancet. 2019;394(10199):652–62. doi:10.1016/S0140-6736(19)30955-9
8. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 populationrepresentative studies with 104 million participants. Lancet. 2021;398(10304):957–80. doi:10.1016/S0140-6736(21)01330-1
9. Lin DS, Wang TD, Buranakitjaroen P, Chen CH, Cheng HM, Chia YC et al. Angiotensin receptor neprilysin inhibitor as a novel antihypertensive drug: evidence from Asia and around the globe. J Clin Hypertens (Greenwich). 2021;23:556–67. doi:10.1111/jch.14120.
10. Izzo JL, Zappe DH, Jia Y, Hafeez K, Zhang J. Efficacy and safety of crystalline valsartan/sacubitril (lcz696) compared with placebo and combinations of free valsartan and sacubitril in patients with systolic hypertension: the RATIO study. Cardiovasc Pharmacol. 2017;69:374–381. doi:10.1097/FJC.0000000000000485
11. Jackson AM, Jhund SP, Anand AS, Düngen HD, Lam CSP, Lefkowitz MP et al. Sacubitril–valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction. Euro Heart J. 2021;42:3741–3752. doi:10.1093/eurheartj/ehab499
12. Geng Q, Yan R, Wang Z, Hou F. Effects of LCZ696 (Sacubitril/Valsartan) on Blood Pressure in Patients with Hypertension: A Meta-Analysis of Randomized Controlled Trials/ Cardiology 2020;145:589–598. doi:10.1159/000507327
13. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993–1004. doi:10.1056/NEJMoa1409077
14. Russian Society of Cardiology (RSC). Chronic heart failure. Clinical guidelines 2020. Russian Journal of Cardiology. 2020;25(11):4083. doi:10.15829/1560-4071-2020-4083. In Russian.
15. Zhang M, Zou Y, Li Y, Wang H, Sun W, Liu B. The history and mystery of sacubitril/valsartan: From clinical trial to the real world. Front Cardiovasc Med. 2023–10:1102521. doi:10.3389/fcvm.2023.1102521
16. Kario K, Rakugi H, Yarimizu D, Morita Y, Eguchi S, Iekushi K. Twenty‐four‐hour blood pressure‐lowering efficacy of sacubitril/valsartan versus olmesartan in japanese patients with essential hypertension based on nocturnal blood pressure dipping status: a post hoc analysis of data from a randomized, double‐ blind multicenter study. J Am Heart Assoc. 2023;12:e027612; doi:10.1161/JAHA.122.027612
17. Malik AH, Aronow WS. Efficacy of Sacubitril/Valsartan in hypertension. Am J Ther. 2022 May-Jun 01;29(3):e322 e333. doi:10.1097/MJT.0000000000000925
18. Ryazanov AS, Kapitonov KI, Makarovskaya MV, Kudryavtsev AA. The results of the use of angiotensin receptor inhibitors and neprilisin in secondary functional mitral regurgitation in outpatient practice. Annals of the Russian Academy of Medical Sciences. 2020;75(5):514–522. doi:10.15690/vramn1462. In Russian.
19. Kobalava ZD, Lazarev PV, Baleeva LV. Tactics of a cardiologist. Practical guide. M.: GEOTARMedia, 2022. ISBN: 978-5-9704-5815-0. In Russian.
20. Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and metaanalysis. Lancet. 2016;387(10022):957–967. doi:10.1016/S0140-6736(15)01225-8
21. Supasyndh O, Sun N, Kario K, Hafeez K, Zhang J. Longterm (52 week) safety and efficacy of Sacubitril/valsartan in Asian patients with hypertension. Hypertens Res. 2017;40:472–6. doi:10.1038/hr.2016.151
22. Ruilope LM, Dukat A, Bohm M, Lacourciere Y, Gong J, Lefkowitz MP. Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study. Lancet. 2010;375:1255–66. doi:10.1016/S0140-6736(09)61966-8
23. Kario K, Sun N, Chiang FT, Supasyndh O, Baek SH, Inubushi-Molessa A et al. Efficacy and safety of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Asian patients with hypertension: a randomized, double-blind, placebocontrolled study. Hypertension. 2014;63:698–705. doi:10.1161/HYPERTENSIONAHA.113.02002
Supplementary files
Review
For citations:
Ryazanov A.S., Melnikova L.V., Makarovskaya M.V., Kechina O.V. Efficacy of sacubitril/valsartan versus valsartan in patients with arterial hypertension. "Arterial’naya Gipertenziya" ("Arterial Hypertension"). 2024;30(2):198-206. (In Russ.) https://doi.org/10.18705/1607-419X-2024-2375. EDN: VHPBYX
Views:
556
Email this article 